COMMUNIQUÉS West-GlobeNewswire

LifeMD Reports Third Quarter 2024 Results

07/11/2024 - 22:05

Total revenues increased 38% year-over-year to $53.4 million with telehealth revenue up 65% Record gross margin of 90.6%, up 300 basis points from the year-ago period Adjusted EBITDA increased 33% to $3.7 million [...]

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

07/11/2024 - 22:05

Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical [...]

Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance

07/11/2024 - 22:05

Highlights Third quarter revenue grew 11% year-over-year to $213 million , driven by Pharmacogenomics ( 34% ) and Prenatal ( 10% ) and progress on payor coverage and revenue cycle initiatives. Third quarter GAAP net [...]

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

07/11/2024 - 22:05

Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4’24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver Diseases’ (AASLD’s [...]

Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting

07/11/2024 - 22:05

Preliminary data demonstrate durable and dose-dependent T cell responses targeting KRAS mutations and induced responses to patient-specific neoantigens Correlation observed between disease-free survival (“DFS”) and T [...]

Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

07/11/2024 - 22:05

SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological [...]

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

07/11/2024 - 22:05

Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-end Cash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md., Nov. 07, 2024 (GLOBE [...]

Lifeward Announces Appointment of Robert J. Marshall to Its Board of Directors

07/11/2024 - 22:05

Financial executive brings over 30 years of experience and leadership in financial management and strategy MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“ [...]

Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results

07/11/2024 - 22:05

GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year Strong cumulative prescriber growth, 45% year-over-year increase 52% year-over-year prescription [...]

Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

07/11/2024 - 22:10

Pre-planned Phase 3 Reliance II interim analysis, anticipated by YE 2024, could represent an important de-risking event for REL-1017 and the Company Phase 1 study for REL-P11 for metabolic disease expected to begin by [...]

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

07/11/2024 - 22:10

- Phase 1a dose escalation for CX-904 (EGFR-CD3 PROBODY® T-cell engager) continues to advance. Potential Phase 1b initiation in 2025. - - Phase 1 study of CX-2051 (EpCAM PROBODY® ADC) in advanced colorectal cancer (CRC [...]

GENFIT : Information financière du troisième trimestre 2024

07/11/2024 - 22:10

Trésorerie et équivalents de trésorerie s’élevant à 96,0 millions d’euros au 30 septembre 2024 59,7 millions d’euros de revenus des neuf premiers mois de 2024, dont 48,7 millions d'euros de paiement d'étape facturés en [...]

GENFIT Reports Third Quarter 2024 Financial Information

07/11/2024 - 22:10

Cash and cash equivalents totaled €96.0 million as of September 30, 2024 €59.7 million in revenues for the nine months ended September 30, 2024, including the €48.7 million milestone invoiced in June 2024 (received in [...]

Dyne Therapeutics to Present at Upcoming Investor Conferences

07/11/2024 - 22:15

WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with [...]

AMN Healthcare Announces Third Quarter 2024 Results

07/11/2024 - 22:15

Quarterly revenue of $688 million ; GAAP EPS of $0.18 and adjusted EPS of $0.61 DALLAS, Nov. 07, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc. (NYSE: AMN), the leader and innovator in total talent solutions for [...]

Mural Oncology Presents Clinical and Preclinical Data Across its Pipeline at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

07/11/2024 - 22:15

Less frequent IV dosing with nemvaleukin in patients with select advanced solid tumors, including ovarian cancer and mucosal melanoma, showed tumor site-specific pharmacodynamic activity and immune activation [...]

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

07/11/2024 - 22:15

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies [...]

Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update

07/11/2024 - 22:30

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate [...]

BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates

07/11/2024 - 22:30

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents sufficient to fund [...]